Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.58 |
| ▸ | DRD5 | P21918 | 2/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | POLA1 | P09884 | 6/20 | 0.34 |
| ▸ | HRH2 | P25021 | 1/20 | 0.33 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.33 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11704751 | 0.90 | OPRM1 (0.63) | OPRM1OPRD1OPRK1POLA1EHMT2 | |
| SCHEMBL21360805 | 0.86 | OPRM1 (0.58) | OPRM1OPRD1OPRK1POLA1EHMT2 | |
| SCHEMBL22477265 | 0.84 | OPRM1 (0.56) | OPRM1OPRD1OPRK1POLA1EHMT2 | |
| SCHEMBL21360672 | 0.83 | OPRM1 (0.67) | OPRM1DRD5OPRD1OPRK1POLA1 | |
| SCHEMBL21360866 | 0.83 | OPRM1 (0.55) | OPRM1OPRD1OPRK1POLA1EHMT2 | |
| SCHEMBL21424663 | 0.79 | OPRM1 (0.69) | OPRM1OPRK1POLA1ALDH1A1KMT2A | |
| SCHEMBL11700409 | 0.79 | OPRM1 (0.69) | OPRM1OPRK1POLA1ALDH1A1KMT2A | |
| SCHEMBL21424563 | 0.79 | OPRM1 (0.69) | OPRM1OPRK1POLA1ALDH1A1KMT2A | |
| SCHEMBL21042348 | 0.79 | OPRM1 (0.69) | OPRM1OPRK1POLA1ALDH1A1KMT2A | |
| SCHEMBL11700412 | 0.79 | OPRM1 (0.69) | OPRM1OPRK1POLA1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3401306-B1 | DEZOCINE ANALOGUE | SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) | 2020-09-30 | — | — | EP | disclosed |
| US-10414718-B2 | Dezocine analogue | SHANDONG DANHONG PHARMACEUTICAL CO., LTD. (CN) | 2019-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414718-B2 | Dezocine analogue | DDO, DDC, DAO | OPRM1 9/4885DRD5 232/4885OPRD1 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.